KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 108 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 4.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 42 | -62.5% | 0.00% | – |
| Q1 2022 | $2,000 | -88.2% | 112 | -88.8% | 0.00% | -100.0% |
| Q3 2021 | $17,000 | -63.0% | 1,000 | -44.4% | 0.00% | -60.0% |
| Q1 2021 | $46,000 | +206.7% | 1,800 | +44.0% | 0.01% | +66.7% |
| Q3 2019 | $15,000 | +200.0% | 1,250 | +316.7% | 0.01% | +200.0% |
| Q4 2018 | $5,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |